The aim of ALT GIST is to determine whether an alternating treatment approach - using Imatinib and Regorafenib - improves disease control in patients with advanced (metastatic) gastrointestinal stromal tumours. Read More

The SCOT trial has helped researchers answer an important health question about bowel cancer treatment. Its results may change the way some bowel cancers are treated in the future. Read More

The primary aim of the ALaCaRT study is to determine whether laparoscopic-assisted resection is not inferior (or equivalent) to open rectal resection as a safe, effective oncologic approach to rectal cancer. Read More

This trial compares the outcome of patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) expressing KIT (CD117) treated with low dose imatinib versus high dose imatinib. Read More

PETACC-6 aims to investigate if using a combination of capecitabine with oxaliplatin as chemotherapy in the pre- and post-operative treatment setting reduces the risk of recurrence or death in patients with locally advanced rectal cancer. Read More

The aim of InterAACT is to compare two different chemotherapy regimens for the treatment of inoperable locally advanced or metastatic anal cancer to demonstrate which is more effective and less toxic for patients with this disease. Read More

The ICECREAM study aims to provide important data on the optimal use of currently available therapeutics in patients with metastatic colorectal cancer who have progressed on standard chemotherapy options. The trial is designed to answer two questions in parallel. Read More

The primary objective of the GAP trial is to determine the effect of pre-operative chemotherapy in patients with pancreatic cancer. Read More

The DOCTOR study aims to compare the effectiveness of pre-operative treatment with cisplatin, 5 fluorouracil and docetaxel, with or without radiotherapy, in treating people who have shown a poor early response to standard chemotherapy for adenocarcinoma of the oesophagus and/or gastroesophageal junction.  Read More

The Adjuvant GIST study (also known as EORTC 62024) investigated Imatinib in people with resectable GISTs. Read More